Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Summary not available.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 3:00 p.m. PT in San Francisco.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.enanta.com, and a replay will be archived for at least 30 days following the presentation.
Summary not available.
Enanta Pharmaceuticals (NASDAQ:ENTA) said company management will participate in investor conferences in November and December 2025. Jefferies London Global Healthcare Conference fireside chat is scheduled for Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET. Evercore Healthcare Conference fireside chat is scheduled for Wednesday, December 3, 2025 at 8:20 a.m. ET.
A live webcast of each event will be available on the company’s Investors page under Events and Presentations at www.enanta.com, with replays archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) presented new clinical data for two oral RSV antivirals at IDWeek 2025: zelicapavir (EDP-938), an N‑protein inhibitor, and EDP‑323, an L‑protein inhibitor. A post hoc analysis of a Phase 2 pediatric trial (n=96) found zelicapavir shortened median time to complete resolution of RSV symptoms to 6.99 days vs 8.60 days for placebo and sustained resolution to 6.99 vs 10.68 days. Human viral challenge Phase 2a data for EDP‑323 showed rapid symptom and viral load reductions (total symptom AUC reductions: 73% 200mg, 61% 600mg, pooled 67%; viral load AUC reductions: 87% 200mg, 85% 600mg) and strong post‑exposure prophylaxis (PEP) effect: 0% infections in 45 treated vs 26% (6/23) placebo, p<0.001. Both programs reported similar adverse event rates versus placebo and no treatment‑related discontinuations.
Enanta (NASDAQ:ENTA) will present clinical data for two oral RSV candidates, zelicapavir (EDP-938) and EDP-323, at IDWeek 2025 held October 19–22, 2025 in Atlanta and virtually. Zelicapavir has a rapid-fire talk and a poster on October 20 reporting shortened RSV symptom duration in a randomized, double-blind, placebo-controlled pediatric trial (children 28 days–36 months). EDP-323 has an oral presentation on October 20 plus a poster on October 22 reporting rapid reductions in RSV symptoms and viral load after human viral challenge. Posters will be posted on the conference platform and the company website.
Enanta (NASDAQ:ENTA) announced on October 2, 2025 the closing of an upsized underwritten public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares sold pursuant to full exercise of the underwriters’ option. Gross proceeds to Enanta were $74.75 million before underwriting discounts, commissions and offering expenses. All shares were offered by Enanta. Net proceeds will be used, together with existing cash and investments, to fund clinical trials, research and development, working capital and general corporate purposes. J.P. Morgan, Jefferies and Evercore ISI acted as joint book‑running managers. The offering was made under a Form S‑3 shelf registration effective February 8, 2024.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced the pricing of an upsized public offering of 6.5 million shares of common stock at $10.00 per share. The offering is expected to generate gross proceeds of $65.0 million before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price. J.P. Morgan, Jefferies, and Evercore ISI are serving as joint book-running managers. The offering, made under a shelf registration statement, is expected to close on October 2, 2025.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced a proposed public offering of common stock worth $50.0 million. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million of shares at the public offering price, less underwriting discounts and commissions.
The offering will be managed jointly by J.P. Morgan, Jefferies, and Evercore ISI as book-running managers. The offering is being made through a shelf registration statement on Form S-3 that became effective on February 8, 2024. The completion of the offering is subject to market and other conditions.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline results from its Phase 2b RSVHR study of zelicapavir, a novel N-protein inhibitor for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution for patients with COPD, CHF, or age ≥75 (HR3 population).
Key findings include a lower hospitalization rate in the zelicapavir group (1.7%) versus placebo (5.0%), and a 4-5 day faster median time to undetectable viral load. The drug showed statistically significant improvement in Patient Global Impression of Severity scores and demonstrated a favorable safety profile. The study enrolled 186 subjects, with 121 receiving zelicapavir and 65 receiving placebo.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
